Nebulizer

BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

Retrieved on: 
Wednesday, October 4, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the completion of patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”). The Company remains on track to report results from Part 2 of the study in November 2023.

Key Points: 
  • and NESS ZIONA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the completion of patient dosing in Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”).
  • The Company remains on track to report results from Part 2 of the study in November 2023.
  • “BX004 has been designed to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • “With patient dosing now complete in Part 2 of our Phase 1b/2a study, we remain on track to announce results next month.

Respiratory Devices Global Market - Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023

The "Respiratory Devices Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Devices Global Market - Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The respiratory care devices global market is estimated is expected to grow at a mid single digit CAGR from 2022 to 2029 to reach $24,866.6 million by 2029.
  • Technological advancements in respiratory care devices and funding for the development of innovative respiratory technologies further boost the growth of market.
  • Whereas rising use of non - invasive respiratory care devices, advancements in respiratory care devices, funding for the development of innovative respiratory care technologies and favorable reimbursement are providing immense opportunities to the market.

Global Home Health Market Report 2022: Introduction of AI, Big Data, and Automation Present New Avenues for Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, May 5, 2023

The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Home Health Market Size, Share, Growth Analysis, By Product, By Service - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • Old people demand more patient-centric healthcare services, which increases the demand for healthcare workers and agencies, this is expected to drive the market growth.
  • This report provides in-depth analysis of Global Home Health market.
  • The market for home health care will provide more than just health care because of the pandemic.

Synergy Life Science Releases Nebi, a Groundbreaking, Portable Nebulizer

Retrieved on: 
Wednesday, January 25, 2023

BUFORD, Ga. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Synergy Life Science, Inc. (“Synergy”), a company pioneering the development of novel ingredients and innovative products for the consumer health and wellness market, has developed Nebi : the first pocket-sized and fully battery-operated nebulizer for use in a variety of applications.

Key Points: 
  • BUFORD, Ga. , Jan. 25, 2023 (GLOBE NEWSWIRE) -- Synergy Life Science, Inc. (“Synergy”), a company pioneering the development of novel ingredients and innovative products for the consumer health and wellness market, has developed Nebi : the first pocket-sized and fully battery-operated nebulizer for use in a variety of applications.
  • Evidence now definitively shows that vapes and e-cigarettes — often touted as healthy alternatives to traditional smoking — are extremely harmful to the lungs.
  • “Developing novel technologies and unique delivery methods for active ingredients have been cornerstones of my career,” says Synergy CEO and Co-founder Chris Gerlach.
  • Contact Synergy Life Science directly here with any inquiries to stay up-to-date on new information and regarding investment opportunities.

Global COPD Drug Delivery Devices Market Report 2022-2027: Rise in Focus on Smart or Digital Inhalers for Administration of COPD Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022

The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.

Key Points: 
  • The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global COPD Drug Delivery Devices Market.
  • The analyst analyses the Global COPD Drug Delivery Devices Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global COPD Drug Delivery Devices Market.

BRONCUS'S DISPOSABLE NEBULIZING MICRO-CATHETER FOR ENDOSCOPE WAS APPROVED FOR MARKETING IN CHINA AND ITS APPLICATIONS IN DRUG-DEVICE COMBINATION WILL BE BROADENED

Retrieved on: 
Monday, October 31, 2022

Currently, the Product is the only nebulizing micro-catheter product on the market which is approved and also protected by multiple patents in China.

Key Points: 
  • Currently, the Product is the only nebulizing micro-catheter product on the market which is approved and also protected by multiple patents in China.
  • Its application spans across multiple indications and can be compatible with a variety of drugs, broadening the application of drug-device combination in the field of lung disease treatment.
  • The drug distribution can be more uniform and the local drug concentration can be significantly increased, thereby directly enhancing the treatment effect.
  • The Company has been researching interventional pulmonary devices for years, and the Nebulizing Micro-catheter is the first achievement of the Company in the field of drug-device combination.

Global Chronic Obstructive Pulmonary Disease Treatment Devices Report to 2027 - Market Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022

The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027.
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:
    The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals.
  • Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.

Global Nebulizers Market Report 2022: Covid-19 Resulted in Surge in Demand for Nebulizers and Increased Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022

The "Global Nebulizers Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nebulizers Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The nebulizer devices market consists of sales of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis, and COPD.
  • The market is divided by portability into portable nebulizers and tabletop nebulizers.
  • The current Covid-19 pandemic has resulted in a surge in demand for nebulizers.

The Worldwide Therapeutic Respiratory Devices Industry is Anticipated to Reach $16.1 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022

The global therapeutic respiratory devices market size is anticipated to reach USD 16.1 billion by 2030.

Key Points: 
  • The global therapeutic respiratory devices market size is anticipated to reach USD 16.1 billion by 2030.
  • A growing geriatric population base, rapid technological advancements, and increasing prevalence of respiratory diseases are the key factors that are driving the market.
  • Nowadays, respiratory monitoring devices use software applications for the collection and analysis of data from ventilators equipped with the health system.
  • The global increase in the cases of respiratory diseases is one of the major factors that are driving the market for therapeutic respiratory devices.

Piezo Direct Offers New Custom Manufacturing of Stainless Steel Piezo Atomizers

Retrieved on: 
Thursday, March 10, 2022

BURLINGAME, Calif., March 10, 2022 /PRNewswire-PRWeb/ -- Piezo Direct now offers fully customizable piezo atomizers in stainless steel material for medical and commercial applications.

Key Points: 
  • BURLINGAME, Calif., March 10, 2022 /PRNewswire-PRWeb/ -- Piezo Direct now offers fully customizable piezo atomizers in stainless steel material for medical and commercial applications.
  • Piezo Direct does not carry any piezoelectric ceramics off the shelf, and custom piezo atomizers have proven to be the best solution for such sensitive applications.
  • Piezo atomizers follow the same principle as piezo sensors and piezo transducers by creating a mechanical response to an electrical input.
  • For more information about Piezo Direct's fully custom capabilities and piezoelectric ceramics, please contact Piezo Direct at 650-375-7003 or [email protected] to learn more about custom piezo elements .